Science and Innovation - Bristol Myers Squibb - Year In Review
Bristol Myers Squibb has improved the lives of millions of people with our rich history of transformative medical breakthroughs. We’re changing the way medicines are developed with our innovative technologies and science. Using data science, advanced clinical trial solutions and robust digital tools including artificial intelligence and machine learning, we are accelerating our pipeline to deliver on the true potential of our science so that we can get therapies to patients in need.
Two powerful forces behind three
product launches in 2022: mechanistic
modeling & brainpower
The future of pharmaceutical research is already here at Bristol Myers Squibb.
Three unique drugs launched by the company in 2022 are proof that new approaches can accelerate results.
Those medicines target three different diseases — Opdualag treats melanoma; Camzyos, hypertrophic cardiomyopathy; and Sotyktu, plaque psoriasis — and yet, they share one important trait.
All were developed with the help of mechanistic modeling, using a suite of mathematical techniques to analyze and make predictions about complex biological systems.
AI and federated learning for better, faster clinical trials
As artificial intelligence (AI) programs achieve exponential gains in power and sophistication, Bristol Myers Squibb (BMS) is exploring ways to leverage such technologies at many stages of the drug-development process. In June 2022, the company signed a partnership agreement with AI developer Owkin, aimed at boosting the precision and speed of clinical trials.
Sustainability in 2022 and beyond
As a leading global biopharmaceutical company, Bristol Myers Squibb develops and delivers high-quality products that help people around the world suffering from serious diseases.
That’s a great responsibility — and it’s closely connected to our critical accountability to be good stewards of the global environment. In every aspect of our business, we seek to ensure that our vital work treating patients does not create impacts that damage the health of communities and ecosystems.
R&D Pipeline
Content from the 2022 Annual Report
Note: Above pipeline excludes clinical collaborations
* Development Partnership: ABECM (ide-cel): 2seventy bio; AHR: Ikena Oncology; Anti-Tau: Prothena; CAMZYOS in China, Singapore, Thailand, Macau, HK, Taiwan: LianBio; Claudin 18.2 ADC: LaNova Medicines; CD3xPSCA: Avencell; eIF2b Activator: Evotec; ELIQUIS: Pfizer; EMPLICITI: Abbvie; farletuzumab ecteribulin: Eisai; HSP47: Nitto Denko Corporation; rHuPH20: Halozyme; IDHIFA: Servier; MAGEA4/8 TCER: Immatics; milvexian: Janssen Pharmaceuticals, Inc,; OPDIVO, YERVOY, OPDUALAG: Ono; REBLOZYL: Merck; SHP2 Inhibitor: BridgeBio Pharma; TIGIT Bispecific: Agenus; PKCO Inhibitor: Exscientia
∧ Trial(s) exploring various combinations
#Partner-run study